US69366J2006 - Common Stock - After market: 48.04 0 (0%)
NASDAQ:PTCT (2/3/2023, 7:03:22 PM)+0.68 (+1.44%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 10-27 2022-10-27/amc | Earnings (Next) | 02-20 2023-02-20 |
Ins Owners | 1.07% | Inst Owners | 105.35% |
Market Cap | 3.45B | Shares | 71.88M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 74.29 |
IPO | 06-20 2013-06-20 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.
PTC THERAPEUTICS INC
100 Corporate Ct
South Plainfield NEW JERSEY 07080
P: 19082227000.0
CEO: Stuart W. Peltz
Employees: 1252
Website: https://www.ptcbio.com/
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an...
Here you can normally see the latest stock twits on PTCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: